Ignite Creation Date:
2024-05-05 @ 11:30 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00064090
Status:
COMPLETED
Last Update Posted:
2013-07-18
First Post:
2003-07-08
Brief Title:
3-AP and Cytarabine in Treating Patients With Hematologic Cancer
Sponsor:
Vion Pharmaceuticals
Organization:
National Cancer Institute NCI
Conditions & Keywords Data
Conditions:
| Name |
|---|
| MyelodysplasticMyeloproliferative Neoplasms |
| Leukemia |
| Myelodysplastic Syndromes |
Keywords:
| Name | View |
|---|---|
| recurrent adult acute lymphoblastic leukemia | View |
| recurrent adult acute myeloid leukemia | View |
| blastic phase chronic myelogenous leukemia | View |
| refractory chronic lymphocytic leukemia | View |
| relapsing chronic myelogenous leukemia | View |
| chronic myelomonocytic leukemia | View |
| refractory anemia with excess blasts in transformation | View |
| previously treated myelodysplastic syndromes | View |
| atypical chronic myeloid leukemia BCR-ABL1 negative | View |
| myelodysplasticmyeloproliferative neoplasm unclassifiable | View |
| adult acute myeloid leukemia with t821q22q22 | View |
| adult acute myeloid leukemia with t1616p13q22 | View |
| adult acute myeloid leukemia with inv16p13q22 | View |
| refractory anemia with excess blasts | View |
| adult acute myeloid leukemia with 11q23 MLL abnormalities | View |
| adult acute myeloid leukemia with t1517q22q12 | View |